Resveratrol and the eye: activity and molecular mechanisms

Review Article

Abstract

Purpose

Alcohol consumption is inversely correlated with the incidence of cardiovascular disease. It is thought that red wine is specifically responsible for these cardiovascular benefits, due to its ability to reduce vascular inflammation, facilitate vasorelaxation, and inhibit angiogenesis. This is because of its high polyphenolic content. Resveratrol is the main biologically active polyphenol within red wine. Owing to its vascular-enhancing properties, resveratrol may be effective in the microcirculation of the eye, thereby helping prevent ocular diseases such as age-related macular degeneration, diabetic retinopathy, and glaucoma. Such conditions are accountable for worldwide prevalence of visual loss.

Method

A review of the relevant literature was conducted on the ScienceDirect, Web of Science, and PubMed databases. Key words used to carry out the searches included ‘red wine’, ‘polyphenols’, ‘resveratrol’, ‘eye’ and ‘ocular’. Articles relating to the effects of resveratrol on the eye were reviewed.

Results

The protective effects of resveratrol within the eye are extensive. It has been demonstrated to have anti-oxidant, anti-apoptotic, anti-tumourogenic, anti-inflammatory, anti-angiogenic and vasorelaxant properties. There are potential benefits of resveratrol supplementation across a wide range of ocular diseases. The molecular mechanisms underlying these protective actions are diverse.

Conclusion

Evidence suggests that resveratrol may have potential in the treatment of several ocular diseases. However, while there are many studies indicating plausible biological mechanisms using animal models and in-vitro retinal cells there is a paucity of human research. The evidence base for the use of resveratrol in the management of ocular diseases needs to be increased before recommendations can be made for the use of resveratrol as an ocular supplement.

Keywords

Age-related macular degeneration Alcohol Diabetic retinopathy Polyphenols Red wine Resveratrol Retinopathy of prematurity 

References

  1. 1.
    Heberden W (1786) Some account of a disorder of the breast. Med Trans R Coll Physicians (London) 2:59–67Google Scholar
  2. 2.
    Klatsky AL, Friedman GD, Armstrong MA, Kipp H (2003) Wine, liquor, beer and mortality. Am J Epidemiol 158:585–595PubMedGoogle Scholar
  3. 3.
    St Leger AS, Moore F, Cochrane AL (1979) Factors associated with cardiomortality in developed countries with particular reference to consumption of wine. Lancet 1:1017–1020PubMedGoogle Scholar
  4. 4.
    Renaud S, de Lorgeril M (1992) Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339:1523–1526PubMedGoogle Scholar
  5. 5.
    German JB, Walzem RL (2000) The health benefits of wine. Annu Rev Nutr 20:561–593PubMedGoogle Scholar
  6. 6.
    Vinson JA, Hontz BA (1995) Phenol antioxidant index: Comparative antioxidant effectiveness of red and white wines. J Agric Food Chem 43:401–403Google Scholar
  7. 7.
    Cordova AC, Jackson LS, Berk-Schlessel DW, Sumpio BE (2005) The cardiovascular protective effect of red wine. J Am Coll Surg 200:428–439PubMedGoogle Scholar
  8. 8.
    Eng ET, Williams D, Mandava U, Kirma N, Tekmal RR, Chen S (2001) Suppression of aromatase (estrogen synthetase) by red wine phytochemicals. Breast Cancer Res Treat 67:133–146PubMedGoogle Scholar
  9. 9.
    Ruano-Ravina A, Figueiras A, Barros-Dios JM (2004) Type of wine and risk of lung cancer: a case-control study in Spain. Thorax 59:981–985PubMedCentralPubMedGoogle Scholar
  10. 10.
    Sieman EH, Creasy LL (1992) Concentration of phytoalexin resveratrol in wine. Am J Enol Vitic 43:49–52Google Scholar
  11. 11.
    Marambaud P, Zhao H, Davies P (2005) Resveratrol promotes clearance of Alzheimer’s disease amyloid-beta peptides. J Biol Chem 280:37377–37382PubMedGoogle Scholar
  12. 12.
    Vine RP, Harkness EM, Linton SJ (2002) Enology (winemaking). In: Winemaking, from grape growing to marketplace, 2nd edn. Kluwer Academic/Plenum, New York, pp 102-118Google Scholar
  13. 13.
    Waterhouse AL (2002) Wine phenolics. Ann NY Acad Sci 957:21–36PubMedGoogle Scholar
  14. 14.
    Cordova AC (2009) Sumpio BE. Polyphenols are medicine: Is it time to prescribe red wine for our patients? Int J Angiol 18:111–117PubMedCentralPubMedGoogle Scholar
  15. 15.
    King RE, Bomser JA, Min DB (2006) Bioactivity of resveratrol. Comp Rev Food Sci Food Saf 5:65–70Google Scholar
  16. 16.
    Lyons M, Yu C, Toma RB et al (2003) Resveratrol in raw and baked blueberries and bilberries. J Agric Food Chem 51:5867–5870PubMedGoogle Scholar
  17. 17.
    Wang Y, Catane F, Yang Y, Roderick R, Van Breemen RB (2002) An LC-MS method for analysing total resveratrol in grape juice, cranberry juice and in wine. J Agric Food Chem 50:431–435PubMedGoogle Scholar
  18. 18.
    Langcake P, Pryce RJ (1976) The production of resveratrol by vitis vinifera and other members of the vitacea as a response to infection or injury. Physiol Plant Pathol 9:77–86Google Scholar
  19. 19.
    Jeandet P, Bessis R, Maume BF, Meunier P, Peyron D, Trollat P (1995) Effect of enological practices on the resveratrol isomer content of wine. J Agric Food Chem 43:316–319Google Scholar
  20. 20.
    Nonomura S, Kanagawa H, Makimoto A (1963) Chemical constituents of polygonaceous plants. Studies on the components of Ko-jo-kon (Polygonum cuspidatum SIEB et ZUCC). Yakugaku Zasshi 83:983–988Google Scholar
  21. 21.
    Jayatilake GS, Jayasuriya H, Lee ES et al (1993) Kinase inhibitors from Polygonum cuspidatum. J Nat Prod 56:1805–1810PubMedGoogle Scholar
  22. 22.
    Creasy LL, Coffee M (1988) Phytoalexin production potential of grape berries. J Am Soc Hortic Sci 113:230–234Google Scholar
  23. 23.
    Frémont L (2000) Biological effects of resveratrol. Life Sci 66:663–673PubMedGoogle Scholar
  24. 24.
    Soleas GJ, Goldberg DM (1995) Influences of viticultural and oenological factors on changes in cis- and trans-resveratrol in commercial wines. J Wine Res 6:107–22Google Scholar
  25. 25.
    Lamikanra O, Grimm CC, Rodin JB, Inyang ID (1996) Hydroxylated stilbenes in selected American wines. J Agric Food Chem 44:1111–1115Google Scholar
  26. 26.
    Alonso ÁM, Domínguez C, Guillén DA, Barroso CG (2002) Determination of antioxidant power of red and white wines by a new electrochemical method and its correlation with polyphenolic content. J Agric Food Chem 50:3112–3115PubMedGoogle Scholar
  27. 27.
    Li G, Luna C, Liton PB, Navarro I, Epstein DL, Gonzalez P (2007) Sustained stress response after oxidative stress in trabecular meshwork cells. Mol Vis 13:2282–2288PubMedCentralPubMedGoogle Scholar
  28. 28.
    Luna C, Li G, Liton PB, Qiu J, Epstein DL, Challa P, Gonzalez P (2009) Resveratrol prevents the expression of glaucoma markers induced by chronic oxidative stress in trabecular meshwork cells. Food Chem Toxicol 47:198–204PubMedCentralPubMedGoogle Scholar
  29. 29.
    Doganay S, Borazan M, Iraz M, Cigremis Y (2006) The effect of resveratrol in experimental cataract model formed by sodium selenite. Curr Eye Res 31:147–153PubMedGoogle Scholar
  30. 30.
    Hightower KR, McCready JP (1991) Effect of selenite on epithelium of cultured rabbit lens. Invest Ophthalmol Vis Sci 32:406–409PubMedGoogle Scholar
  31. 31.
    Soufi FG, Mohammad-Nejad D, Ahmadieh H (2012) Resveratrol improves diabetic retinopathy possibly through oxidative stress – nuclear factor kappaB – apoptosis pathway. Pharmacol Rep 64:1505–1514PubMedGoogle Scholar
  32. 32.
    Yar AS, Menevse S, Dogan I, Alp E, Ergin V, Cumaoglu A, Menevse A (2012) Investigation of ocular neovascularization-related genes and oxidative stress in diabetic rat eye tissues after resveratrol treatment. J Med Food 15:391–398PubMedGoogle Scholar
  33. 33.
    Kim YH, Kim YS, Roh GS, Choi WS, Cho GJ (2012) Resveratrol blocks diabetes-induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas. Acta Ophthalmol (Copenh) 90:e31–e37Google Scholar
  34. 34.
    Li C, Wang L, Huang K, Zheng L (2012) Endoplasmic reticulum stress in retinal vascular degeneration: protective role of resveratrol. Invest Ophthalmol Vis Sci 53:3241–3249PubMedGoogle Scholar
  35. 35.
    Sheu SJ, Liu NC, Ou CC, Bee YS, Chen SC, Lin HC, Chan JYH (2013) Resveratrol stimulates mitochondrial bioenergetics to protect retinal pigment epithelial cells from oxidative damage. Invest Ophthalmol Vis Sci 54:6426–6438PubMedGoogle Scholar
  36. 36.
    Lopez PF, Grossniklaus HE, Aaberg TM, Sternburg P, Capone A, Lambert HM (1992) Pathogenetic mechanisms in anterior proliferative vitreoretinopathy. Am J Ophthalmol 114:257–270PubMedGoogle Scholar
  37. 37.
    Cai J, Nelson KC, Wu M, Sternberg P, Jones DP (2000) Oxidative damage and protection of the RPE. Prog Retin Eye Res 19:205–221PubMedGoogle Scholar
  38. 38.
    Kanski JJ, Bowling B (2001) Ophthalmology: A systematic approach, 7th edn. Elsevier Saunders, EdinburghGoogle Scholar
  39. 39.
    Beatty S, Koh HH, Henson D, Boulton M (2000) The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 45:115–134PubMedGoogle Scholar
  40. 40.
    King RE, Kent KD, Bomser JA (2005) Resveratrol reduces oxidation and proliferation of human retinal pigment epithelial cells via extracellular signal-regulated kinase inhibition. Chem Biol Interact 151:143–149PubMedGoogle Scholar
  41. 41.
    Hecquet C, Lefevre G, Valtink M, Engelmann K, Mascarelli F (2002) Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE proliferation. Invest Ophthalmol Vis Sci 43:3091–3098PubMedGoogle Scholar
  42. 42.
    Szende B, Tyihák H, Király-Véghely (2000) Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures. Exp Mol Med 32:88–92PubMedGoogle Scholar
  43. 43.
    Zoberi I, Bradbury CM, Curry HA, Bisht KS, Goswami PC, Roti Roti JL, Gius D (2002) Radiosensitising and anti-proliferative effects of resveratrol in two human cervical tumor cell lines. Cancer Lett 175:165–173PubMedGoogle Scholar
  44. 44.
    Qin S, Lu Y, Rodrigues G (2014) Resveratrol protects RPE cells from sodium iodate by modulating PPARα and PPARδ. Expl Eye Res 118:100–108Google Scholar
  45. 45.
    Anekonda TS, Adamus G (2008) Resveratrol prevents antibody-induced apoptotic death of retinal cells through upregulation of Sirt1 and Ku70. BMC Res Notes 1:122PubMedCentralPubMedGoogle Scholar
  46. 46.
    Magrys A, Anekonda T, Ren G, Adamus G (2007) The role of anti-alpha-enolase autoantibodies in pathogenicity of autoimmune-mediated retinopathy. J Clin Immunol 27:181–192PubMedGoogle Scholar
  47. 47.
    Adamus G, Webb S, Shiraga S, Duvoisin RM (2006) Anti-recoverin antibodies induce an increase in intracellular calcium, leading to apoptosis in retinal cells. J Autoimmun 26:146–153PubMedGoogle Scholar
  48. 48.
    Kubota S, Kurihara T, Ebinuma M, Kubota M, Yuki K, Sasaki M, Noda K, Ozawa Y, Oike Y, Ishida S, Tsubota K (2010) Resveratrol prevents light-induced retinal degeneration via suppressing activator protein-1 activation. Am J Pathol 177:1725–1731PubMedCentralPubMedGoogle Scholar
  49. 49.
    van Ginkel PR, Darjatmoko SR, Sareen D, Subramanian L, Bhattacharya S, Lindstrom MJ, Albert DM, Polans AS (2008) Resveratrol inhibits uveal melanoma tumor growth via early mitochondrial dysfunction. Invest Ophthalmol Vis Sci 49:1299–1306PubMedCentralPubMedGoogle Scholar
  50. 50.
    Kanski JJ, Bowling B (2011) Clinical ophthalmology: a systematic approach, 7th edn. Elsevier Saunders, EdinburghGoogle Scholar
  51. 51.
    Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CWW, Fong HHS, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM (1997) Cancer chemopreventative activity of resveratrol, a natural product derived from grapes. Science 275:218–220PubMedGoogle Scholar
  52. 52.
    Sareen D, van Ginkel PR, Takach JC, Mohiuddin A, Darjatmoko ADM, Polans AS (2006) Mitochondria as the primary target of resveratrol-induced apoptosis in human retinoblastoma cells. Invest Ophthalmol Vis Sci 47:3708–3716PubMedGoogle Scholar
  53. 53.
    Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM, Dannedberg AJ (1998) Resveratrol inhibits cyclooxgenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Bio Chem 1273:21875–21882Google Scholar
  54. 54.
    Pendurthi UR, Williams JT, Rao LVM (1999) Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells: a possible mechanism for the cardiovascular benefits associated with moderate wine consumption. Arterioscler Thromb Vasc Biol 19:419–426PubMedGoogle Scholar
  55. 55.
    Culpitt SV, Rogers DF, Fenwick PS, Shah P, de Matos C, Russell REK, Barnes PJ, Donnelly LE (2003) Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 58:942–946PubMedCentralPubMedGoogle Scholar
  56. 56.
    Manna SK, Mukhopadhyay A, Aggarwal BB (2000) Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κB, Activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 164:6509–6519PubMedGoogle Scholar
  57. 57.
    Ambati J, Anand A, Fernandez S, Sakurai E, Lynn BC, Kuziel WA, Rollins BJ, Ambati BK (2003) An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med 9:1390–1397PubMedGoogle Scholar
  58. 58.
    Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP (2004) A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18:1450–1452PubMedGoogle Scholar
  59. 59.
    Satici A, Guzey M, Gurler B, Vural H, Gurkan T (2003) Malondialdehyde and antioxidant enzyme levels in the aqueous humor of rabbits in endotoxin-induced uveitis. Eur J Ophthalmol 13:779–783PubMedGoogle Scholar
  60. 60.
    Kubota S, Kurihara T, Mochimaru H, Satofuka S, Noda K, Ozawa Y, Oike Y, Ishida S, Tsubota K (2009) Prevention of ocular inflammation in endotoxin-induced uveitis with resveratrol by inhibiting oxidative damage and nuclear factor–ĸB activation. Invest Ophthalmol Vis Sci 50:3512–3519PubMedGoogle Scholar
  61. 61.
    Baldwin AS Jr (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14:649–683PubMedGoogle Scholar
  62. 62.
    Fuentes ME, Durham SK, Swerdel MR, Lewin AC, Barton DS, Megill JR, Bravo R, Lira SA (1995) Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1. J Immunol 155:5769–5776PubMedGoogle Scholar
  63. 63.
    Becker MD, Garman K, Whitcup SM, Planck SR, Rosenbaum JT (2001) Inhibition of leukocyte sticking and infiltration, but not rolling, by antibodies to ICAM-1 and LFA-1 in murine endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 42:2563–2566PubMedGoogle Scholar
  64. 64.
    Bordone L, Guarente L (2005) Calorie restriction SIRT1 and metabolism: understanding longevity. Nat Rev Mol Cell Biol 6:298–305PubMedGoogle Scholar
  65. 65.
    Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski ZLL, Scherer B, Sinclair DA (2003) Small molecule activators of sirtuins extends Saccharomyces cerevisiae lifespan. Nature 425:191–196PubMedGoogle Scholar
  66. 66.
    Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, Sinclair D (2004) Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430:686–689PubMedGoogle Scholar
  67. 67.
    Valenzano DR, Terzibasi E, Genade T, Cattaneo A, Domenici L, Cellerino A (2006) Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol 16:296–300PubMedGoogle Scholar
  68. 68.
    Milne JC, Lambert PD, Schenk S (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450:712–716PubMedCentralPubMedGoogle Scholar
  69. 69.
    Araki T, Sasaki Y, Millbrandt J (2004) Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305:1010–1013PubMedGoogle Scholar
  70. 70.
    Schindler KS, Ventura E, Rex TS, Elliott P, Rostami A (2007) SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci 48:3602–3609Google Scholar
  71. 71.
    Khan RS, Fonseca-Kelly Z, Callinan C, Zuo L, Sachdeva MM, Shindler KS (2012) SIRT1 activating compounds reduce oxidative stress and prevent cell death in neuronal cells. Front Cell Neurosci 6:63PubMedCentralPubMedGoogle Scholar
  72. 72.
    Kim SH, Park JH, Kim YJ, Park KH (2013) The neuroprotective effect of resveratrol on retinal ganglion cells after optic nerve transection. Mol Vis 19:1667–1676PubMedCentralPubMedGoogle Scholar
  73. 73.
    Fonseca-Kelly Z, Nassrallah M, Uribe J, Khan RS, Dine K, Dutt M, Shindler KS (2012) Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. Front Neurol 3:84PubMedCentralPubMedGoogle Scholar
  74. 74.
    Zuo L, Khan RS, Lee V, Dine K, Wu W, Shindler KS (2013) SIRT1 Promotes RGC survival and delays loss of function following optic nerve crush. Invest Ophthalmol Vis Sci 54:5097–5102PubMedCentralPubMedGoogle Scholar
  75. 75.
    Vin AP, Hu H, Zhai Y, Von Zee CL, Logeman A, Stubbs EB Jr, Bu P (2013) Neuroprotective effect of resveratrol prophylaxis on experimental retinal ischemic injury. Exp Eye Res 108:72–75PubMedGoogle Scholar
  76. 76.
    Huang W, Li G, Qiu J, Gonzalez P, Challa P (2013) Protective effects of resveratrol in experimental retinal detachment. Plos One 8:9Google Scholar
  77. 77.
    Villaroel M, Garcia-Ramirez M, Corraliza L, Hernandez C, Simo R (2009) Effects of high glucose concentration on the barrier function and the expression of tight junction proteins in human retinal pigment epithelial cells. Exp Eye Res 89:913–920Google Scholar
  78. 78.
    Losso JN, Truax RE, Richard G (2010) trans-Resveratrol inhibits hyperglycemia-induced inflammation and connexin downregulation in retinal pigment epithelial cells. J Agric Food Chem 58:8246–8252PubMedGoogle Scholar
  79. 79.
    Giebel SJ, Menicucci G, McGuire PG, Das A (2005) Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest 85:597–607PubMedGoogle Scholar
  80. 80.
    Malfait M, Gomez P, van Veen TAB, Parys JB, de Smedt H, Vereecke J, Himpens B (2001) Effects of hyperglycemia and protein kinase C on connexin 43 expression in cultured rat retinal pigment epithelial cells. J Membr Biol 181:31–40PubMedGoogle Scholar
  81. 81.
    Richer S, Stiles W, Ulanski L, Carroll D, Podella C (2013) Observation of human retinal remodeling in octogenarians with a resveratrol based nutritional supplement. Nutrients 5:6Google Scholar
  82. 82.
    Hua J, Guerin KI, Chen J, Michan S, Stahl A, Krah NM, Seaward MR, Dennison RJ, Juan AM, Hatton CJ, Sapieha P, Sinclair DA, Smith LEH (2011) Resveratrol inhibits pathologic retinal neovascularization in Vldlr-/- Mice. Invest Ophthalmol Vis Sci 52:2809–2816PubMedCentralPubMedGoogle Scholar
  83. 83.
    Yannuzzi LA, Bardal AM, Freund KB, Chen KJ, Eandi CM, Blodi B (2006) Idiopathic macular telangiectasia. Arch Ophthalmol 124:450–460PubMedGoogle Scholar
  84. 84.
    Kovach JL, Rosenfeld PJ (2009) Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II. Retina 29:27–32PubMedGoogle Scholar
  85. 85.
    Khan AA, Dace DS, Ryazanov AG, Kelly J, Apte RS (2010) Resveratrol regulates pathologic angiogenesis by a eukaryotic elongation factor-2 kinase-regulated pathway. Am J Pathol 177:481–492PubMedCentralPubMedGoogle Scholar
  86. 86.
    Horman S, Browne G, Krause U (2002) Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 12:1419–1423PubMedGoogle Scholar
  87. 87.
    Doganay S, Firat PG, Cankaya C, Kirimlioglu H (2013) Evaluation of the effects of resveratrol and bevacizumab on experimental corneal alkali burn. Burns 39:326–330PubMedGoogle Scholar
  88. 88.
    Kim WT, Suh ES (2010) Retinal protective effects of resveratrol via modulation of nitric oxide synthase on oxygen-induced retinopathy. Korean J Ophthalmol 24:108–118PubMedCentralPubMedGoogle Scholar
  89. 89.
    Miller EC, Capps BE, Sanghani RR, Clemmons DR, Maile LA (2007) Regulation of IGF-I signaling in retinal endothelial cells by hyperglycemia. Invest Ophthalmol Vis Sci 48:3878–3887PubMedGoogle Scholar
  90. 90.
    Nagaoka T, Hein TW, Yoshida A, Kuo L (2007) Resveratrol, a component of red wine, elicits dilation of isolated porcine retinal arterioles: role of nitric oxide and potassium channels. Invest Ophthalmol Vis Sci 48:4232–4239PubMedGoogle Scholar
  91. 91.
    Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32:1377–1382PubMedGoogle Scholar
  92. 92.
    Change4Life (2012) http://www.nhs.uk/Change4Life/Pages/change-for-life.aspx. Accessed 20th February 2013
  93. 93.
    Paulo L, Oleastro M, Gallardo E, Queiroz JA, Domingues F (2001) Antimicrobial properties of resveratrol: a review. In: Mendez-Vilas A (ed) Science against microbial pathogens: communicating current research and technological advances. Formatex Research Center, Spain, pp 1225–1235Google Scholar
  94. 94.
    Chan MMY (2002) Antimicrobial effect of resveratrol on dermatophytes and bacterial pathogens of the skin. Biochem Pharm 63:99–104PubMedGoogle Scholar
  95. 95.
    Frémont L, Belguendouz L, Delpal S (1999) Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids. Life Sci 64:2511–2521PubMedGoogle Scholar
  96. 96.
    Ray PS, Maulik G, Gerald GA, Bertelli AAE, Bertelli A, Das DK (1999) The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radical Biol Med 27:160–9Google Scholar
  97. 97.
    Leonard SS, Xia C, Jiang BH, Stinefelt B, Klandorf H, Harris GK, Shi X (2003) Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem and Biophys Res Comm 309:1017–1026Google Scholar
  98. 98.
    Gehm BD, McAndrews JM, Chien PY, Jameson JL (1997) Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci 94:14138–14143PubMedCentralPubMedGoogle Scholar
  99. 99.
    Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM (2000) Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141:3657–3667PubMedGoogle Scholar
  100. 100.
    Belguendouz L, Fremont L, Linard A (1997) Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem Pharmacol 53:1347–1355PubMedGoogle Scholar
  101. 101.
    Tadolini B, Juliano C, Piu L, Franconi F, Cabrini L (2000) Resveratrol inhibition of lipid peroxidation. Free Radic Res 33:105–114PubMedGoogle Scholar
  102. 102.
    Aziz MH, Kumar R, Ahmad N (2003) Cancer chemoprevention by resveratrol: In vitro and in vivo studies and the underlying mechanisms (Review). Int J Oncol 23:17–28PubMedGoogle Scholar
  103. 103.
    Wang Z, Huang Y, Zou J, Cao K, Xu Y, Wu JM (2002) Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med 9:77–79PubMedGoogle Scholar
  104. 104.
    Shen MY, Hsiao G, Liu CL, Fong TH, Lin KH, Chou DS, Sheu JR (2007) Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br J Haematol 139:475–485PubMedGoogle Scholar
  105. 105.
    Donnelly LE, Newton R, Kennedy GE, Fenwick PS, Leung RHF, Ito K, Russell REK, Barnes PJ (2004) Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am J Physiol Lung Cell Mol Physiol 287:774–783Google Scholar
  106. 106.
    Martin AR, Villegas I, Sánchez-Hidalgo M, de la Lastra CA (2006) The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol 147:873–885PubMedCentralPubMedGoogle Scholar
  107. 107.
    Novakovic A, Gojkovic-Bukarica L, Peric M, Nezic D, Djukanovic B, Markovic-Lipkovski HH (2006) The mechanism of endothelium independent relaxation induced by the wine polyphenol resveratrol in human internal mammary artery. J Pharmacol Sci 101:85–90PubMedGoogle Scholar
  108. 108.
    Rush JW, Quadrilatero J, Levy AS, Ford RJ (2007) Chronic resveratrol enhances endothelium-dependent relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats. Exp Biol Med 232:814–22Google Scholar
  109. 109.
    Jang M, Pezzuto JM (1998) Resveratrol blocks eicosanoid production and chemically-induced cellular transformation: Implications for cancer chemoprevention. Pharm Biol 36:28–34Google Scholar
  110. 110.
    Ahn J, Cho I, Kim S, Kwon D, Ha T (2008) Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J Hepatol 49:1019–1028PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Christina Bola
    • 1
  • Hannah Bartlett
    • 1
  • Frank Eperjesi
    • 1
  1. 1.Ophthalmic Research Group, School of Life and Health SciencesAston UniversityBirminghamUK

Personalised recommendations